Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase (Chemistry & Biology (2014) 21(4) (453–458) (S1074552114000696) (10.1016/j.chembiol.2014.02.011));An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase

Chemistry and Biology

Volumn 21, Issue 4, 2014, Pages 453-458

  Littlefield, Peter ^a   Moasser, Mark M ^b,c   Jura, Natalia ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BOSUTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 3 PSEUDOKINASE; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ERBB3 PROTEIN, HUMAN; NITRILE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING SITE; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DIMERIZATION; DISSOCIATION CONSTANT; DRUG BINDING; ENZYME CONFORMATION; ENZYME STRUCTURE; HUMAN; LIPID MEMBRANE; LIPID VESICLE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; ANILINE COMPOUNDS; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; NITRILES; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, ERBB-3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899638504     PISSN: 10745521     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.07.008     Document Type: Erratum

References (29)

1. P.D. Adams, P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, and R.W. Grosse-Kunstleve et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 66 2010 213 221
2. D.N. Amin, M.R. Campbell, and M.M. Moasser The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics Semin. Cell Dev. Biol. 21 2010 944 950
3. A. Arkhipov, Y. Shan, R. Das, N.F. Endres, M.P. Eastwood, D.E. Wemmer, J. Kuriyan, and D.E. Shaw Architecture and membrane interactions of the EGF receptor Cell 152 2013 557 569
4. S. Blencke, B. Zech, O. Engkvist, Z. Greff, L. Orfi, Z. Horváth, G. Kéri, A. Ullrich, and H. Daub Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors Chem. Biol. 11 2004 691 701
5. J. Boudeau, D. Miranda-Saavedra, G.J. Barton, and D.R. Alessi Emerging roles of pseudokinases Trends Cell Biol. 16 2006 443 452
6. CCP4 (Collaborative Computational Project, Number 4) The CCP4 suite: programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50 1994 760 763
7. 2+/calmodulin- dependent kinase II holoenzyme Cell 146 2011 732 745
8. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, M. Hocker, D.K. Treiber, and P.P. Zarrinkar Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29 2011 1046 1051
9. P. Emsley, B. Lohkamp, W.G. Scott, and K. Cowtan Features and development of Coot Acta Crystallogr. D Biol. Crystallogr. 66 2010 486 501
10. N.F. Endres, R. Das, A.W. Smith, A. Arkhipov, E. Kovacs, Y. Huang, J.G. Pelton, Y. Shan, D.E. Shaw, and D.E. Wemmer et al. Conformational coupling across the plasma membrane in activation of the EGF receptor Cell 152 2013 543 556
11. J.A. Engelman, P.A. Jänne, C. Mermel, J. Pearlberg, T. Mukohara, C. Fleet, K. Cichowski, B.E. Johnson, and L.C. Cantley ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines Proc. Natl. Acad. Sci. USA 102 2005 3788 3793
12. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, R. Alvarado, M.J. Ludlam, D. Stokoe, S.L. Gloor, and G. Vigers et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
13. N. Jura, N.F. Endres, K. Engel, S. Deindl, R. Das, M.H. Lamers, D.E. Wemmer, X. Zhang, and J. Kuriyan Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment Cell 137 2009 1293 1307
14. N. Jura, Y. Shan, X. Cao, D.E. Shaw, and J. Kuriyan Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 Proc. Natl. Acad. Sci. USA 106 2009 21608 21613
15. K. Kani, C.M. Warren, C.S. Kaddis, J.A. Loo, and R. Landgraf Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin J. Biol. Chem. 280 2005 8238 8247
16. A.V. Korennykh, P.F. Egea, A.A. Korostelev, J. Finer-Moore, R.M. Stroud, C. Zhang, K.M. Shokat, and P. Walter Cofactor-mediated conformational control in the bifunctional kinase/RNase Ire1 BMC Biol. 9 2011 48
17. R. Landgraf, and D. Eisenberg Heregulin reverses the oligomerization of HER3 Biochemistry 39 2000 8503 8511
18. A.G.W. Leslie, and H.R. Powell Processing diffraction data with Mosflm R.J. Read, J.L. Sussman, Evolving Methods for Macromolecular Crystallography Volume 245 2007 Springer Dordrecht, the Netherlands 41 51
19. N.M. Levinson, and S.G. Boxer Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain PLoS ONE 7 2012 e29828
20. P. Littlefield, and N. Jura EGFR lung cancer mutants get specialized Proc. Natl. Acad. Sci. USA 110 2013 15169 15170
21. M.E. Noble, J.A. Endicott, and L.N. Johnson Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1805
22. T. Okuzumi, D. Fiedler, C. Zhang, D.C. Gray, B. Aizenstein, R. Hoffman, and K.M. Shokat Inhibitor hijacking of Akt activation Nat. Chem. Biol. 5 2009 484 493
23. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
24. M. Red Brewer, C.H. Yun, D. Lai, M.A. Lemmon, M.J. Eck, and W. Pao Mechanism for activation of mutated epidermal growth factor receptors in lung cancer Proc. Natl. Acad. Sci. USA 110 2013 E3595 E3604
25. N.V. Sergina, M. Rausch, D. Wang, J. Blair, B. Hann, K.M. Shokat, and M.M. Moasser Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445 2007 437 441
26. Y. Shan, M.P. Eastwood, X. Zhang, E.T. Kim, A. Arkhipov, R.O. Dror, J. Jumper, J. Kuriyan, and D.E. Shaw Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization Cell 149 2012 860 870
27. F. Shi, S.E. Telesco, Y. Liu, R. Radhakrishnan, and M.A. Lemmon ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation Proc. Natl. Acad. Sci. USA 107 2010 7692 7697
28. E. Zeqiraj, B.M. Filippi, S. Goldie, I. Navratilova, J. Boudeau, M. Deak, D.R. Alessi, and D.M. van Aalten ATP and MO25α regulate the conformational state of the STRADα pseudokinase and activation of the LKB1 tumour suppressor PLoS Biol. 7 2009 e1000126
29. X. Zhang, J. Gureasko, K. Shen, P.A. Cole, and J. Kuriyan An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125 2006 1137 1149